Panel Discussion: Concurrent Modalities in Cannabinoid Therapeutics: Advances in Synthetic & Botanical Drug Development

• Navigating the differences in the regulatory landscape for botanical and synthetic drugs
• Discussing how research into both fields has contributed to the overall understanding of cannabinoid pharmacology
• Validating effectively scaling up in synthetic drug production versus maintaining API consistency in botanical drugs

Speakers:

Hunter Land

Chief Executive Officer

Lupvindol BioScience